Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).
HC Wainwright & Co. Maintains Buy Rating for Aerie Pharmaceuticals: Here’s What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Aerie Pharmaceuticals (NASDAQ:AERI) and lower its price target from $25.00 to $20.00.
Shares of Aerie Pharmaceuticals are trading down 3.54% over the last 24 hours, at $6.03 per share.
Aerie Pharmaceuticals Q1 EPS $(0.66) Misses $(0.65) Estimate, Sales $29.80M Miss $29.87M Estimate
Aerie Pharmaceuticals (NASDAQ:AERI) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 8.33 percent increase over losses of $(0.72) per share
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
93 Biggest Movers From Friday
Gainers
Inspirato Incorporated (NASDAQ: ISPO) shares surged 50.5% to close at $54.90.
45 Stocks Moving In Friday’s Mid-Day Session
Gainers
KAR Auction Services, Inc. (NYSE: KAR) shares climbed 39.2% to $19.05 after the company agreed to sell its ADESA U.S. physical auction business to Carvana for $2.2 billion. Guggenheim upgraded KAR Auction Services from Sell to Neutral.